EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
EBR:UCB (3/7/2025, 7:00:00 PM)
188.5
-3.55 (-1.85%)
The current stock price of UCB.BR is 188.5 EUR. In the past month the price decreased by -0.4%. In the past year, price increased by 71.52%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
PFE.DE | PFIZER INC | 8.69 | 140.81B |
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,083 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9000
Company Website: https://www.ucb.com
Investor Relations: https://www.ucb.com/investors/
Phone: 3225599999
The current stock price of UCB.BR is 188.5 EUR. The price decreased by -1.85% in the last trading session.
The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.
UCB.BR stock is listed on the Euronext Brussels exchange.
25 analysts have analysed UCB.BR and the average price target is 210.97 EUR. This implies a price increase of 11.92% is expected in the next year compared to the current price of 188.5. Check the UCB SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UCB SA (UCB.BR) has a market capitalization of 36.67B EUR. This makes UCB.BR a Large Cap stock.
UCB SA (UCB.BR) currently has 9000 employees.
UCB SA (UCB.BR) has a support level at 187.74 and a resistance level at 195.11. Check the full technical report for a detailed analysis of UCB.BR support and resistance levels.
The Revenue of UCB SA (UCB.BR) is expected to grow by 16.59% in the next year. Check the estimates tab for more information on the UCB.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UCB SA (UCB.BR) has a dividend yield of 0.5%. The yearly dividend amount is currently 1.36. Check the full fundamental report for a detailed analysis of UCB.BR dividend history, reliability and sustainability.
UCB SA (UCB.BR) will report earnings on 2025-07-23.
The PE ratio for UCB SA (UCB.BR) is 34.4. This is based on the reported non-GAAP earnings per share of 5.48 and the current share price of 188.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for UCB.BR.
ChartMill assigns a technical rating of 8 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 96.03% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR has only an average score on both its financial health and profitability.
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 5.48. The EPS increased by 211.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 17.31% | ||
ROA | 6.14% | ||
ROE | 10.62% | ||
Debt/Equity | 0.3 |
ChartMill assigns a Buy % Consensus number of 75% to UCB.BR. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 62.35% and a revenue growth 16.59% for UCB.BR